导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.98% | 1008/4587 |
| 近一周 | -0.17% | 916/5248 |
| 近一月 | -1.20% | 1032/5205 |
| 近一季 | -11.03% | 3703/5018 |
| 近半年 | -2.99% | 2253/4725 |
| 近一年 | 9.52% | 1156/4241 |
| 近两年 | 97.60% | 637/2862 |
| 近三年 | 48.12% | 574/2171 |
| 成立以来 | 218.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.18% 563/4961 |
17.43% 1467/5312 |
- - |
- - |
| 2025 | 36.95% 921/4813 |
5.87% 718/3635 |
5.52% 577/4076 |
22.28% 1662/4524 |
0.27% 2090/4813 |
| 2024 | 3.89% 1904/3463 |
-6.49% 2058/2808 |
-7.74% 2118/3014 |
14.48% 1962/3129 |
5.19% 627/3463 |
| 2023 | -1.84% 536/2656 |
11.09% 349/2280 |
-1.23% 455/2385 |
-8.07% 1658/2515 |
-2.69% 516/2655 |
| 2022 | -12.82% 301/2207 |
-12.37% 606/1919 |
8.12% 388/2016 |
-8.66% 217/2113 |
0.73% 1460/2208 |
| 2021 | 32.17% 58/1822 |
1.02% 265/1255 |
15.95% 216/1330 |
5.59% 267/1466 |
6.86% 200/1822 |
| 2020 | 34.31% 441/1250 |
3.55% 116/1028 |
23.90% 182/1067 |
6.04% 878/1164 |
-1.28% 1099/1184 |
| 2019 | 32.76% 444/1092 |
28.55% 303/739 |
-4.58% 425/788 |
-0.60% 602/850 |
8.89% 274/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信中证1000指数增强A VS. 长安沪深300非周期A(740101) |